WAKMAR2, a Prognosis-related Enhancer RNA in Gastric Cancer

Yankai Zhang  
Peking University

Yichao Yan (✉️ 18810057399@126.com)  
Peking University  https://orcid.org/0000-0002-3816-7610

Ning Ning  
Peking University

Zhanlong Shen  
Peking University

Yingjiang Ye  
Peking university

Research article

Keywords: WAKMAR2, Enhancer RNA, Prognosis, Immunotherapy, Gastric cancer

DOI: https://doi.org/10.21203/rs.3.rs-97295/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose An increasing number of long non-coding RNAs (lncRNAs) are thought to be associated with gastric cancer (GC). A lncRNA subclass that promotes enhancer function is called enhancer RNA (eRNA). We aimed to identify an eRNA that can predict GC prognosis and response to immune checkpoint inhibitors (ICIs).

Methods Kaplan–Meier survival analysis was utilized to screen eRNA which can predict the prognosis of GC (P <0.05). The method of Spearman correlation analysis was employed in the filtration of target genes related to eRNA (r> 0.4, P <0.001). According to the median of WAKMAR2 expression, the patients were subdivided into low expression group and high expression group. Subsequently, differences of immune checkpoint-related genes and immune cell infiltration between the two groups were further explored. Furthermore, we analyzed the correlation of WAKMAR2 with tumor mutation burden (TMB) and microsatellite instability (MSI) in GC and other types of cancer.

Results WAKMAR2 and its target gene TNFAIP3 entered the subsequent analysis. Patients with high-WAKMAR2 expression had a favorable prognosis compared to patients with low-WAKMAR2 expression (P = 0.048). Immune checkpoint-related genes (PD-L1, CTLA4, PDCD1, LAG3) in the WAKMAR2 high-expression group were also highly expressed, except for B7-H3. In addition, infiltration levels of B cells naive, T cells CD8, T cells CD4 memory activated, as well as Macrophages M1 in high-WAKMAR2 group were greater than in low-WAKMAR2 group. Last, the expression of WAKMAR2 in GC was significantly correlated with TMB and MSI.

Conclusion WAKMAR2, a new eRNA, is a promising biomarker that can be used to predict the overall survival (OS) of GC patients, and WAKMAR2 expression can be utilized to identify ICB responders in GC, providing new insights for immunotherapy strategies.

Introduction

Gastric cancer (GC) is a kind of malignant tumor with poor therapeutic effect, whose incidence and mortality rate shows a gradual upward trend[1]. Over the last few years, there has been major developments in GC diagnosis and treatment, but its prognosis is still poor[2]. At present, the most commonly used methods to evaluate the prognosis of GC are still histological diagnosis and TNM staging[3]. It is well described that GC is a highly heterogeneous disease[4]. Clinically, it is difficult to predict the prognosis of GC patients accurately by using the existing evaluation methods. Therefore, biomarkers that can accurately predict the prognosis of GC would help improve the clinical outcome of these patients.

There is mounting evidence showing that aberrant expression of long non-coding RNA (lncRNA) is closely related to numerous diseases, including cancer[5, 6]. ERNA is a non-coding RNA transcribed from enhancer. Some recent studies have found that enhancer dysfunction is considered a key process of tumorigenesis[7, 8]. Up to the present time, there is no research on GC related eRNA.
Checkpoint inhibitors targeting cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death 1 (PD1) pave the way for the era of cancer immunotherapy, thus changing the way of cancer treatment[9, 10]. However, although anti-PD-1 mAb is a promising approach for the treatment of patients with advanced GC, its response rate is still limited, so it is necessary to develop new strategies to maximize the efficacy of ICIs. However, although advanced GC patients can choose anti-PD-1 mAb treatment, the response rate is disappointing.

There is evidence to indicate the importance of the tumor microenvironment (TME) in tumor progression[11]. Tumor-infiltrating immune cells (TIICs) are one of the components of the TME, and it was a potential indicator to evaluate the therapeutic effect[12]. Many people had explored the link between TMB and immunotherapy response[13, 14]. Higher TMB produce more neoantigens, the greater the possibility of being recognized by immune cells, so TMB is a good marker for predicting the response of immunotherapy[15, 16]. Microsatellites (MS) are composed of repeating sequences of 1–6 nucleotides[17]. Its loss or gain is called MSI, which is also a powerful biomarker for immunotherapy[18].

In this study, we found that the expression of WAKMAR2 was related to the prognosis of GC, and it may be an immune-related eRNA. Its expression was related to the expression of immune checkpoint genes and the abundance of immune infiltrating cells. In addition, we also studied the correlation between WAKMAR2 expression and TMB and MSI in pan-cancer. This may help to accurately immunotherapy GC patients.

**Materials And Methods**

**Data extraction**

The gene expression, mutation data, clinical and survival data of GC and other type cancers were downloaded from the UCSC-Xena browser. From previous literature[19], we obtained a list of enhancer RNA and its predicted target genes.

**Screening and identifying eRNA**

Patients were sorted into two groups according to the median level of eRNA expression. The Kaplan-Meier method was used to generate two groups of high and low expression survival curves. The difference of survival curve was determined by Log-rank test(p<0.05). The spearman method was used to analyze the correlation between eRNA and predicted target genes (correlation coefficient r > 0.4, P <0.001). It was considered as a candidate eRNA only if the following conditions were met, which was related to the overall survival of patients with GC (p <0.05) and the correlation coefficient between eRNA and target genes meets the conditions (r> 0.4, P <0.001).

**GO and KEGG enrichment analysis**

In addition to the predicted targets, other transcripts that were significantly related to eRNA were obtained through correlation analysis. In order to study the possible molecular mechanism of eRNA related coding
genes, GO and KEGG pathway enrichment analysis was performed using the R package ("DOSE", "clusterProfiler", "enrichplot"). GO terms with both p- and q-value of <0.05 were considered as significant. KEGG terms with p < 0.05 were considered to be significantly enriched.

**Relationship between eRNA expression and immune checkpoint-related genes**

We extracted expression data of immune checkpoint-related genes (PD-L1, CTLA4, PDCD1, LAG3, B7-H3) from the expression matrix of GC. The Wilcoxon rank sum test was utilized to compare the expression difference of immune checkpoint-related genes between high and low expression eRNA groups.

**CIBERSORT analysis**

CIBERSORT is an analysis tool that can infer the expression matrix of 22 human leukocyte subtypes based on RNA-seq data. In order to quantify TIICs in GC samples, we use CIBERSORT algorithm. The Wilcoxon rank sum test was performed to compare the different abundance of immune infiltration between the two groups (eRNA high expression group and low expression group).

**Correlation analysis of eRNA expression and TMB and MSI**

We download the mutation data of 33 tumors from the UCSC website, and then calculate the TMB value of each sample in GC through a Perl script calculation. The MSI value of all tumor sample was obtained from the previous literature. Spearman correlation coefficient was calculated to assess the strength of the correlation between eRNA expression of GC TMB and MSI. In addition, we also conducted the above correlation analysis in other types of tumors.

**Verification in pan-cancer**

In order to determine whether eRNA expression can predict the OS of other types of tumors, we performed pan-cancer survival verification. In addition, we also verified the correlation between eRNA and target gene expression in pan-cancer.

**Statistical analysis**

Statistical analyses were conducted in R statistical package Version 3.6.3. Kaplan-Meier analysis was completed using R package ‘survival’. The Wilcoxon rank sum test was used for comparison between two groups of clinicopathological parameters, and Kruskal-Wallis (K-W) test was used for three or more groups. All correlation coefficients were calculated by Spearman correlation analysis. For all analyses, two-tailed P-value < 0.05 was thought significant.

**Results**

**Identification of eRNA associated with prognosis of GC**
We used a Perl script to convert the eRNA transcript ID into a gene symbol for subsequent analysis. Then, the expression of eRNA was extracted from the expression matrix of GC and combine it with the survival time. As showed in Table 1, 23 eRNAs significantly related to the OS of GC were filtered by Kaplan-Meier method (p < 0.05). Different from other eRNA, HAGLR has five predicted target genes. Surprisingly, levels of these 23 eRNA were significantly correlated with their predicted levels of target gene mRNAs (r > 0.4, p < 0.001; Table 1).

**LncRNA WAKMAR2 is a Key eRNA in GC**

LncRNA WAKMAR2 was selected as eRNA for further study, and its expression level was positively correlated with its predicted target gene TNFAIP3 level. Compared with patients in the WAKMAR2 high expression group, patients in the WAKMAR2 low expression group had a shorter OS (Figure 1A, p < 0.05). As showed in Figure 1B, WAKMAR2 and TNFAIP3 mRNA levels are moderately correlated (r = 0.55, p < 0.001). It is worth noting that we studied the prognostic effect of WAKMAR2 in other cancer types and its correlation with TNFAIP3 mRNA levels. The impact of WAKMAR2 on OS and TNFAIP3 was specific for 8 types of cancer only, which were GC, Adrenocortical carcinoma, Breast invasive carcinoma, Brain Lower Grade Glioma, Mesothelioma, Pancreatic adenocarcinoma, Pheochromocytoma and Paraganglioma and Thymoma (Table 2).

**Association between WAKMAR2 expression and clinicopathological features**

In order to verify the potential clinical utility of WAKMAR2 expression, the clinicopathological features of 371 GC patients were included in this study (Table 3). Figure 2 summarizes the associations between WAKMAR2 expression and clinicopathological features. Compared with Stage I and Stage II, WAKMAR2 expression level was higher in Stage III (Stage I vs III, p < 0.05; Stage II vs III, p < 0.01). However, compared with stage II and stage III, WAKMAR2 expression was lower in stage IV (Stage II vs IV, p < 0.05; Stage III vs IV, p < 0.001). The difference in WAKMAR2 expression level between Grade2 and Grade3 was statistically significant (G2 vs G3, p < 0.001). Furthermore, higher WAKMAR2 expression levels correlated with advanced T stage (T2 vs T3, p < 0.01; T2 vs 4, p < 0.01). However, no difference was observed between age, gender, N stage, M stage, family history, neoplasm status, pylori infection, and radiation therapy.

**Functional enrichment analysis**

To further elucidate WAKMAR2 function, we used correlation analysis to identify significantly co-expressed genes in GC. Including TNFAIP3, a total of 2335 transcripts were significantly associated with WAKMAR2 (p<0.001). Co-expressed genes underwent GO enrichment analysis to identify the functions (Figure 3A). In BP category, "T cell activation", "T cell differentiation" and "lymphocyte differentiation" has been enriched, which means that co-expressed genes affect the function of the immune system in tumor microenvironment. Enriched CC terms included “phagocytic cup”, “mast cell granule”, “immunological synapse”, and the enriched MF terms included "cytidine deaminase activity", “G protein-coupled chemoattractant receptor activity", “chemokine receptor activity”. In addition, to determine the co-expressed gene enrichment pathway, we conducted KEGG enrichment analysis, including "Purine
metabolism", "Primary bile acid biosynthesis" and "Taurine and hypotaurine metabolism" (Figure 3B). We analyzed the correlation between genes which were enriched in the "immune response-activating cell surface receptor signaling pathway" and WAKMAR2 (p < 0.001). Immune genes with Spearman correlation coefficient > 0.40 were listed in Table 4.

To evaluate the clinical significance of immune checkpoint-related genes

The median value of WAKMAR2 expression was used as a cut-off value, patients were divided into high and low-expression groups. In this study, high-expression group patients exhibited higher gene expression of PDL1 (p < 0.001, Figure 4A), CTLA4 (p < 0.001, Figure 4B), PDCD1 (p < 0.001, Figure 4C) and LAG3 (p < 0.001, Figure 4D). However, the expression level of B7-H3 was higher in the low-expression group (p < 0.001, Figure 4E). The results of the study indicated that patients in the high-expression group were expected to be candidates for ICIs. Inhibitors against B7-H3 seem to have better therapeutic effects on patients in the low-expression group.

Differences in the abundance of immune cells between groups with high and low WAKMAR2 expression

Co-expressed genes have been shown to be involved in immune regulation, so we wanted to further analyze the differences in the immune fractions between the WAKMAR2 high-expression group and the WAKMAR2 low-expression group. The fractions of infiltrating immune cells were calculated by the CIBERSORT algorithm. Among the 22 leukocyte subtypes, B cells naive, T cells CD8, T cells CD4 memory activated and Macrophages M1 was positively correlated with WAKMAR2 expression (Figure 5). However, in the WAKMAR2 low-expression group, T cells CD4 memory resting, Macrophages M0, Macrophages M2, Mast cells activated, and Neutrophils accounted for a high proportion (Figure 5).

Correlation of WAKMAR2 expression level with TMB and MSI in different cancer types

As depicted in Figure 6A, the expression of WAKMAR2 was negatively correlated with TMB in Stomach adenocarcinoma (r = -0.288, p<0.001), Esophageal carcinoma (r = -0.222,p<0.01), Head and Neck squamous cell carcinoma (r = -0.154,p<0.001), Kidney renal clear cell carcinoma(r = -0.206,p<0.001), Liver hepatocellular carcinoma (r = -0.222,p<0.001), Lung adenocarcinoma (r = -0.121,p<0.01), Lung squamous cell carcinoma (r = -0.130,p<0.01), Pancreatic adenocarcinoma (r = -0.417,p<0.001), Pheochromocytoma and Paraganglioma (r=-0.295,p<0.001), Prostate adenocarcinoma (r = -0.267,p<0.001), Thyroid carcinoma (r = -0.161,p<0.001) and Thymoma (r = -0.768,p<0.001). On the contrary, the expression of WAKMAR2 was negatively correlated with TMB in Adrenocortical carcinoma (r = 0.277, p<0.05), Brian Lower Grade Glioma (r = 0.298, p<0.001), Ovarian serous cystadenocarcinoma (r = 0.133, p<0.05).

Similarly, the expression of WAKMAR2 was significantly correlated with MSI in Stomach adenocarcinoma (r = -0.128,p<0.05),Breast invasive carcinoma (r = 0.089,p<0.01), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (r = -0.460,p<0.01), Esophageal carcinoma (r = -0.220,p<0.01), Kidney renal clear cell carcinoma (r = -0.117,p<0.05), Kidney renal papillary cell carcinoma (r = -0.119,p<0.05), Rectum adenocarcinoma (r = 0.164,p<0.05), Thyroid carcinoma (r = 0.123,p<0.01) (Figure 6B).
Discussion

ERNA is a special type of IncRNAs, which originate in the region of gene enhancers and can affect the transcription of corresponding genes through cis-acting. According to our screening criteria, WAKMAR2 was selected to enter the follow-up study. The original name of WAKMAR2 is LOC100130476, its genomic locus is very special, its transcription direction is antisense, and there is an overlapping region with the TNFAIP3 gene body and promoter part[20, 21]. The expression of WAKMAR2 and TNFAIP3 has a strong correlation in various tumor types. A previous study confirmed that LOC100130476 was down-regulated in gastric cardiac adenocarcinoma tissue, suggesting that it had a tumor suppressive effect[22]. In addition, another study proved that LOC100130476 was significantly down-regulated in esophageal cancer cell lines and primary esophageal squamous cell carcinoma tissues, and its up-regulation could inhibit the proliferation and invasion ability of cancer cells[23]. In other words, the survival rate of patients with cardia adenocarcinoma and esophageal cancer with low expression of LOC100130476 is poor, which is consistent with the results of our study.

As we all know, the higher the expression level of immune checkpoint-related genes in tumor tissues, the better the therapeutic effect of ICI. There is now accumulated evidence suggests that ICI have therapeutic potential in GC[24, 25]. Nevertheless, only a few patients benefit from ICI. In addition, tumor immune microenvironment plays a crucial role in tumor progression. It is particularly important to identify precisely those GC patients who will benefit most from ICI. Very coincidentally, the expression level of WAKMAR2 is a potential marker to accurately distinguish these patients. We explored the association between WAKMAR2 and immune checkpoint-related genes for expression. The expression levels of PDL1, CTLA4, PDCD1 and LAG3 were significantly increased in WAKMAR2 high expression group. However, the level of B7-H3 increased significantly in the low expression group. This result provides strong evidence for our hypothesis that eRNA expression levels can be used to screen which patients are more likely to respond to ICI.

Immune-cell infiltration is one of the characteristics of many cancers, including GC. Disorders of immune system function are related to the occurrence of malignant tumors[26]. Our study found that the abundance of B cells naive, T cells CD8, T cells CD4 memory activated and Macrophage M1 in WAKMAR2 high expression group were higher; T cells CD4 memory resting, Macrophages M0, Macrophages M2, Mast cells activated, and Neutrophils have high abundance in the low expression group of WAKMAR2. These results suggested that the expression of WAKMAR2 can affect the signatures of immune cell infiltration. Based on the results of previous studies, dysregulation of immune components might be the reason for the difference in survival between the two patient groups[27]. The results of this study were in agreement with the findings of previous reports. For example, with regard to the relationship between CD8+ T cells infiltration in tumors and survival of patients with GC, previous studies have shown that high CD8+ T cell expression levels are associated with a good prognosis[28]. The increase of M1 macrophages may be related to the better OS of GC patients[29, 30]. In another such report, M2 macrophages are involved in the development of gastric cancer peritoneal dissemination[31]. Mast cells not only to promote the metastasis of GC, but also regulate the tumor microenvironment by...
Neutrophils promote migration and invasion of GC cells by activating the ERK pathway and inducing epithelial-mesenchymal transition, suggesting that neutrophils may play a crucial role in GC metastasis. Therefore, this study provides a new understanding of the role of WAKMAR2 in the regulation of TIICs.

With the development of high-throughput sequencing technology, detecting TMB and MSI from genome sequencing is a new method to predict the efficacy of ICB, and it has been proven to be effective in a variety of tumors. A potential problem in daily clinical practice is that TMB and MSI detection was expensive and time-consuming. Therefore, it is particularly important to explore alternative biomarkers for TMB and MSI. In the study of GC, the expression of WAKMAR2 has a certain correlation with TMB and MSI, and may be used as a potential marker to replace them. In the process of pan-cancer verification, it was surprisingly found that TMB of thymoma had a negative correlation with WAKMAR2, and the correlation coefficient was as high as 0.768. This result will provide new insights for immunotherapy of thymoma.

**Conclusions**

In conclusion, we have identified a new prognostic marker for GC, the enhancer RNA WAKMAR2. Patients in the WAKMAR2 high expression group may have a better prognosis when receiving ICI therapy.

**Declarations**

**Ethics approval and consent to participate**

No permissions were required to use the repository data.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by National Natural Science Foundation of China [grant number 81702336] and Peking University International Hospital Research Grant (No.: YN2019XQ01).

**Authors’ contributions**

This research was conducted in collaboration with all authors. Yankai Zhang and Yichao Yan performed the data curation and analysis. Yankai Zhang and Ning Ning analyzed and interpreted the results. Yankai
Zhang, Zhanlong Shen and Yingjiang Ye drafted and reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We are very grateful for the support of the National Natural Science Foundation of China and the Peking University International Hospital Research Grant.

Availability of data and materials

The raw data of this study was obtained from the UCSC Xena website portal, which is a publicly available database.

References

1. Poorolajal J, Moradi L, Mohammadi Y, Cheraghi Z, Gohari-Ensaf F: Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiology and health 2020, 42:e2020004.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 2010, 127(12):2893-2917.
3. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F: Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014, 23(5):700-713.
4. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K et al.: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature medicine 2015, 21(5):449-456.
5. Arun G, Diermeier SD, Spector DL: Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends in molecular medicine 2018, 24(3):257-277.
6. Fang Y, Fullwood MJ: Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer. Genomics, proteomics & bioinformatics 2016, 14(1):42-54.
7. Herz HM, Hu D, Shilatifard A: Enhancer malfunction in cancer. Molecular cell 2014, 53(6):859-866.
8. Sur I, Taipale J: The role of enhancers in cancer. Nature reviews Cancer 2016, 16(8):483-493.
9. Kono K: Advances in cancer immunotherapy for gastroenterological malignancy. Annals of gastroenterological surgery 2018, 2(4):244-245.
10. Sharma P, Allison JP: The future of immune checkpoint therapy. Science (New York, NY) 2015, 348(6230):56-61.
11. Ma B, Wells A, Clark AM: The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment. Seminars in cancer biology 2020, 60:138-147.
12. Gajewski TF, Schreiber H, Fu YX: Innate and adaptive immune cells in the tumor microenvironment. *Nature immunology* 2013, 14(10):1014-1022.

13. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC: CAR T cell immunotherapy for human cancer. *Science (New York, NY)* 2018, 359(6382):1361-1365.

14. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* 2016, 165(1):35-44.

15. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science (New York, NY)* 2015, 348(6230):124-128.

16. Klebanov N, Artomov M, Goggins WB, Daly E, Daly MJ, Tsao H: Burden of unique and low prevalence somatic mutations correlates with cancer survival. *Scientific reports* 2019, 9(1):4848.

17. Garrido-Ramos MA: Satellite DNA: An Evolving Topic. *Genes* 2017, 8(9).

18. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science (New York, NY)* 2017, 357(6349):409-413.

19. Vučićević D, Corradin O, Ntini E, Scacheri PC, Ørom UA: Long ncRNA expression associates with tissue-specific enhancers. *Cell cycle (Georgetown, Tex)* 2015, 14(2):253-260.

20. Herter EK, Li D, Toma MA, Vij M, Li X, Visscher D, Wang A, Chu T, Sommar P, Blomqvist L et al: WAKMAR2, a Long Noncoding RNA Downregulated in Human Chronic Wounds, Modulates Keratinocyte Motility and Production of Inflammatory Chemokines. *The Journal of investigative dermatology* 2019, 139(6):1373-1384.

21. Devos M, Mogilenko DA, Fleury S, Gilbert B, Becquart C, Quemener S, Dehondt H, Tougaard P, Staels B, Bachert C et al: Keratinocyte Expression of A20/TNFAIP3 Controls Skin Inflammation Associated with Atopic Dermatitis and Psoriasis. *The Journal of investigative dermatology* 2019, 139(1):135-145.

22. Guo W, Dong Z, Shi Y, Liu S, Liang J, Guo Y, Guo X, Shen S, Wang G: Methylation-mediated downregulation of long noncoding RNA LOC100130476 in gastric cardia adenocarcinoma. *Clinical & experimental metastasis* 2016, 33(5):497-508.

23. Guo W, Dong Z, Shi Y, Liu S, Liang J, Guo Y, Guo X, Shen S, Shan B: Aberrant methylation-mediated downregulation of long noncoding RNA LOC100130476 correlates with malignant progression of esophageal squamous cell carcinoma. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 2016, 48(8):961-969.

24. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet (London, England)* 2017, 390(10111):2461-2471.

25. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B et al: *Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial*. *The Lancet Oncology* 2016, 17(6):717-726.

26. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M: *Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes*. *Experimental hematology* 2009, 37(5):616-628.e612.

27. Li B, Cui Y, Diehn M, Li R: *Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer*. *JAMA oncology* 2017, 3(11):1529-1537.

28. Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A: *Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients*. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association* 2017, 20(3):407-415.

29. Okita Y, Tanaka H, Ohira M, Muguruma K, Kubo N, Watanabe M, Fukushima W, Hirakawa K: *Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer*. *The Journal of surgical research* 2014, 186(1):192-200.

30. Wang XL, Jiang JT, Wu CP: *Prognostic significance of tumor-associated macrophage infiltration in gastric cancer: a meta-analysis*. *Genetics and molecular research : GMR* 2016, 15(4).

31. Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S et al: *Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination*. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association* 2016, 19(4):1052-1065.

32. Liu X, Jin H, Zhang G, Lin X, Chen C, Sun J, Zhang Y, Zhang Q, Yu J: *Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients*. *PloS one* 2014, 9(9):e106834.

33. Zhang W, Gu J, Chen J, Zhang P, Ji R, Qian H, Xu W, Zhang X: *Interaction with neutrophils promotes gastric cancer cell migration and invasion by inducing epithelial-mesenchymal transition*. *Oncology reports* 2017, 38(5):2959-2966.

34. Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD et al: *Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer*. *Cancer cell* 2018, 33(5):853-861.e854.

### Tables
| Symbol          | Log-Rank P-Value | Predicted Target | Correlation between IncRNA and the Target P-Value | Correlation coefficient r |
|-----------------|------------------|------------------|-----------------------------------------------|---------------------------|
| EMX2OS          | 0.001            | EMX2             | < 0.001                                       | 0.762                     |
| AL021937.3      | 0.001            | SLC5A4           | < 0.001                                       | 0.454                     |
| HAGLR           | 0.002            | HOXD1            | < 0.001                                       | 0.759                     |
| HAGLR           | 0.002            | HOXD3            | < 0.001                                       | 0.557                     |
| HAGLR           | 0.002            | HOXD4            | < 0.001                                       | 0.506                     |
| HAGLR           | 0.002            | HOXD8            | < 0.001                                       | 0.483                     |
| HAGLR           | 0.002            | HOXD9            | < 0.001                                       | 0.454                     |
| RASSF8-AS1      | 0.003            | RASSF8           | < 0.001                                       | 0.882                     |
| CASC16          | 0.005            | TOX3             | < 0.001                                       | 0.490                     |
| NR2F1-AS1       | 0.005            | NR2F1            | < 0.001                                       | 0.855                     |
| ILDR2           | 0.010            | ILDR2            | < 0.001                                       | 1.000                     |
| VLDLR-AS1       | 0.013            | VLDLR            | < 0.001                                       | 0.774                     |
| OTX2-AS1        | 0.016            | OTX2             | < 0.001                                       | 0.505                     |
| ZFHX4-AS1       | 0.017            | ZFHX4            | < 0.001                                       | 0.783                     |
| LINC02381       | 0.018            | HOXC4            | < 0.001                                       | 0.653                     |
| AL445426.1      | 0.025            | WNT2B            | < 0.001                                       | 0.605                     |
| SERPINB9P1      | 0.029            | SERPINB9         | < 0.001                                       | 0.436                     |
| HSD11B1-AS1     | 0.029            | G0S2             | < 0.001                                       | 0.430                     |
| AC002451.1      | 0.036            | PDK4             | < 0.001                                       | 0.663                     |
| AC109479.1      | 0.040            | ADAMTS2          | < 0.001                                       | 0.560                     |
| WDFY3-AS2       | 0.041            | WDFY3            | < 0.001                                       | 0.461                     |
| IGFBP7-AS1      | 0.041            | IGFBP7           | < 0.001                                       | 0.778                     |
| CCDC144NL-AS1   | 0.044            | CCDC144NL        | < 0.001                                       | 0.607                     |
| LINC02519       | 0.045            | THBS2            | < 0.001                                       | 0.450                     |
| Symbol       | Log-Rank P-Value | Predicted Target | Correlation between IncRNA and the Target |
|--------------|-----------------|------------------|------------------------------------------|
|              |                 |                  | P-Value  | Correlation coefficient r |
| LINC01389    | 0.047           | FOXD2            | < 0.001 | 0.443                     |
| WAKMAR2      | 0.048           | TNFAIP3          | < 0.001 | 0.550                     |
| AL355916.1   | 0.049           | HIF1A            | < 0.001 | 0.427                     |
| Tumor Type | Detail | WAKMAR2 and Overall Survival Log-Rank P-Value | WAKMAR2 and TNFAIP3 Correlation P-Value | Correlation Coefficient |
|------------|--------|-----------------------------------------------|-----------------------------------------|------------------------|
| ACC        | Adrenocortical carcinoma | 0.042 | P<0.001 | 0.815 |
| BLCA       | Bladder Urothelial Carcinoma | 0.491 | P<0.001 | 0.732 |
| BRCA       | Breast invasive carcinoma | 0.042 | P<0.001 | 0.791 |
| CESC       | Cervical squamous cell carcinoma and endocervical adenocarcinoma | 0.983 | P<0.001 | 0.575 |
| CHOL       | Cholangiocarcinoma | 0.632 | P<0.001 | 0.715 |
| COAD       | Colon adenocarcinoma | 0.487 | P<0.001 | 0.671 |
| DLBC       | Lymphoid Neoplasm Diffuse Large B-cell Lymphoma | 0.248 | P<0.001 | 0.724 |
| ESCA       | Esophageal carcinoma | 0.871 | P<0.001 | 0.676 |
| GBM        | Glioblastoma multiforme | 0.918 | P<0.001 | 0.428 |
| HNSC       | Head and Neck squamous cell carcinoma | 0.112 | P<0.001 | 0.423 |
| KICH       | Kidney Chromophobe | 0.455 | P<0.001 | 0.620 |
| KIRC       | Kidney renal clear cell carcinoma | 0.873 | P<0.001 | 0.613 |
| KIRP       | Kidney renal papillary cell carcinoma | 0.747 | P<0.001 | 0.600 |
| LAML       | Acute Myeloid Leukemia | 0.353 | P<0.001 | 0.370 |
| LGG        | Brain Lower Grade Glioma | 0.000 | P<0.001 | 0.608 |
| LIHC       | Liver hepatocellular carcinoma | 0.661 | P<0.001 | 0.684 |
| LUAD       | Lung adenocarcinoma | 0.401 | P<0.001 | 0.748 |
| LUSC       | Lung squamous cell carcinoma | 0.659 | P<0.001 | 0.698 |
| MESO       | Mesothelioma | 0.030 | P<0.001 | 0.714 |
| OV         | Ovarian serous cystadenocarcinoma | 0.085 | P<0.001 | 0.507 |
| PAAD       | Pancreatic adenocarcinoma | 0.018 | P<0.001 | 0.661 |
| PCPG       | Pheochromocytoma and Paraganglioma | 0.036 | P<0.001 | 0.585 |
| PRAD       | Prostate adenocarcinoma | 0.458 | P<0.001 | 0.643 |
| READ       | Rectum adenocarcinoma | 0.349 | P<0.001 | 0.643 |
| Code | Description                                      | Value | P-value | Adjusted P-value |
|------|-------------------------------------------------|-------|---------|------------------|
| SARC | Sarcoma                                         | 0.369 | <0.001  | 0.652            |
| SKCM | Skin Cutaneous Melanoma                         | 0.189 | <0.001  | 0.740            |
| STAD | Stomach adenocarcinoma                          | 0.048 | <0.001  | 0.550            |
| TGCT | Testicular Germ Cell Tumors                     | 0.793 | <0.001  | 0.620            |
| THCA | Thyroid carcinoma                               | 0.839 | <0.001  | 0.632            |
| THYM | Thymoma                                         | 0.010 | 0.003   | 0.270            |
| UCEC | Uterine Corpus Endometrial Carcinoma            | 0.933 | <0.001  | 0.489            |
| UCS  | Uterine Carinosarcoma                           | 0.624 | 0.002   | 0.409            |
| UVM  | Uveal Melanoma                                  | 0.654 | <0.001  | 0.775            |
| Covariates         | N (%)     | Covariates         | N (%)     |
|--------------------|-----------|--------------------|-----------|
| **Age**            |           | **M_Stage**        |           |
| <65                | 155 (41.78%) | M0                 | 327 (88.14%) |
| >=65               | 216 (58.22%) | M1                 | 25 (6.74%)   |
| **Gender**         |           | **Family_history** |           |
| Female             | 132 (35.58%) | NO                 | 268 (72.24%) |
| Male               | 239 (64.42%) | YES                | 16 (4.31%)   |
| **Stage**          |           | **Pylori_infection** |           |
| Stage I            | 51 (13.75%) | NO                 | 87 (23.45%)  |
| Stage II           | 110 (29.65%) | YES                | 16 (4.31%)   |
| Stage III          | 150 (40.43%) | NO                 | 143 (38.54%) |
| Stage IV           | 37 (9.97%)  | YES                | 18 (4.85%)   |
| **Grade**          |           | **Neoplasm_status** |           |
| G1                 | 10 (2.7%)  | TUMOR FREE         | 163 (43.94%) |
| G2                 | 133 (35.85%) | unknown            | 136 (36.66%) |
| G3                 | 219 (59.03%) | WITH TUMOR         | 72 (19.41%)  |
| **unknown**        | 23 (6.2%)  | Neoplasm_status    | 18 (4.85%)   |
| **T_Stage**        |           | **Radiation_therapy** |           |
| T1                 | 18 (4.85%)  | NO                 | 234 (63.07%) |
| T2                 | 77 (20.75%) | YES                | 45 (12.13%)  |
| T3                 | 168 (45.28%)|                   |            |
| T4                 | 100 (26.95%)|                   |            |
| **unknown**        | 8 (2.16%)  |                   |            |
| **N_Stage**        |           |                   |            |
| N0                 | 109 (29.38%)|                   |            |
| N1                 | 96 (25.88%) |                   |            |
| N2                 | 75 (20.22%) |                   |            |
|     |       |
|-----|-------|
| N3  | 73(19.68%) |
| unknown | 18(4.85%) |
Table 4
List of immune genes associated with WAKMAR2 expression (r > 0.400, p < 0.001).

| Gene Symbol | Spearman Correlation Coefficient r | Gene Symbol | Spearman Correlation Coefficient r |
|-------------|-----------------------------------|-------------|-----------------------------------|
| ITK         | 0.617                             | MEF2C      | 0.489                             |
| ZAP70       | 0.606                             | PRKCH      | 0.484                             |
| CD226       | 0.603                             | PSMA8      | 0.484                             |
| KLRK1       | 0.593                             | NCKAP1L    | 0.478                             |
| LAT         | 0.578                             | PRKCQ      | 0.474                             |
| ELMO1       | 0.577                             | CD28       | 0.471                             |
| GRAP2       | 0.577                             | NFKBID     | 0.466                             |
| CD3G        | 0.563                             | GPLD1      | 0.464                             |
| PRKCB       | 0.559                             | TRBC1      | 0.456                             |
| FYB1        | 0.556                             | CD79B      | 0.451                             |
| PIK3CD      | 0.553                             | WAS        | 0.450                             |
| TRAT1       | 0.541                             | BTK        | 0.450                             |
| TESPA1      | 0.537                             | CD22       | 0.449                             |
| LAX1        | 0.537                             | PVRIG      | 0.448                             |
| CCR7        | 0.535                             | NCR3       | 0.447                             |
| CTLA4       | 0.530                             | PLCG2      | 0.447                             |
| WIPF1       | 0.530                             | RFTN1      | 0.445                             |
| LPXN        | 0.529                             | CD247      | 0.445                             |
| PTPN22      | 0.526                             | TXK        | 0.442                             |
| KLHL6       | 0.526                             | BTN2A2     | 0.442                             |
| CD160       | 0.525                             | MALT1      | 0.440                             |
| CD19        | 0.523                             | PLCG1      | 0.439                             |
| THEMIS      | 0.521                             | GATA3      | 0.438                             |
| CD3D        | 0.519                             | NFATC2     | 0.436                             |
| SLA2        | 0.518                             | LAT2       | 0.436                             |
| CD38        | 0.515                             | BCL2       | 0.435                             |
| Gene  | Value  | Gene  | Value  |
|-------|--------|-------|--------|
| TRAC  | 0.514  | CYLD  | 0.433  |
| FCRL3 | 0.511  | LCP2  | 0.431  |
| FYN   | 0.509  | CD79A | 0.429  |
| TRBC2 | 0.507  | VAV1  | 0.427  |
| PTPRC | 0.505  | FOXP3 | 0.426  |
| UBASH3A | 0.502  | LCK   | 0.425  |
| MS4A1 | 0.496  | CR2   | 0.419  |
| CD3E  | 0.493  | BLK   | 0.416  |
| MYO1G | 0.493  | CLEC10A | 0.411 |
| STAP1 | 0.491  | THEMIS2 | 0.410 |